Spire Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

Spire Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-148,800	Closed	-$162K	–	2497
2022 Q2	$162K	Hold	148,800	–	–	0.01%	840
2022 Q1	$158K	Buy	148,800 +23,000	+18%	+$21.1K	﹤0.01%	987
2021 Q4	$113K	Buy	125,800 +107,800	+599%	+$113K	﹤0.01%	1353
2021 Q3	$24K	Buy	18,000 +4,000	+29%	+$6.08K	﹤0.01%	1784
2021 Q2	$27K	Buy	14,000 +12,000	+600%	+$41.3K	﹤0.01%	1750
2021 Q1	$9K	Buy	+2,000	New	+$9.31K	﹤0.01%	2450

Other funds holding PLX

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CPA

Capital Performance Advisors Walnut Creek, California $1.5B AUM 21.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Spire Wealth Management's PLX Position: Q3 2022 in Review

Spire Wealth Management sold out of Protalix BioTherapeutics (PLX) in Q3 2022, closing a stake of 148,800 shares — an estimated $162K sold.

Spire Wealth Management first reported a position in PLX in Q1 2021 and held it in 6 quarters. The position peaked at $162K in Q2 2022. 27 funds tracked by Wall St. Rank hold PLX as of Q3 2022.

Spire Wealth Management reported no remaining Protalix BioTherapeutics position as of Q3 2022 after selling out during the quarter.
Spire Wealth Management sold 148,800 Protalix BioTherapeutics shares in Q3 2022, an estimated $162K.
Spire Wealth Management first reported a position in Protalix BioTherapeutics in Q1 2021 and held it in 6 quarters.
Spire Wealth Management's Protalix BioTherapeutics position peaked at $162K in Q2 2022.
27 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.